Escitalopram

Psychedelics may better treat depression and anxiety symptoms than prescription antidepressants for patients with advanced cancer

Retrieved on: 
Lunedì, Aprile 17, 2023
People, Psilocybin, Blood pressure, Review, Trauma, Escitalopram, Drug, Drug Enforcement Administration, Depression, Paroxetine, Senior counsel, Anxiety, Placebo, Cancer, Ground substance, Schedule 1, Research, Emotion, LSD, Meta-analysis, History, Fluoxetine, Schedule, Food and Drug Administration Amendments Act of 2007, Patient, Catharsis, Grammatical mood, Caregiver, FDA, Bias, MDMA, Food, PTSD, Pharmaceutical industry, Nightclub, Meat, Cannabidiol

In people with advanced cancer, psychedelic drugs like psilocybin, LSD and MDMA may significantly reduce the severity of depression and anxiety symptoms.

Key Points: 
  • In people with advanced cancer, psychedelic drugs like psilocybin, LSD and MDMA may significantly reduce the severity of depression and anxiety symptoms.
  • However, current research suggests that available prescription antidepressants do not significantly decrease depressive symptoms in cancer patients compared with a placebo.
  • My team and I recently completed a meta-analysis of five clinical trials examining anxiety and depression symptoms in patients with advanced forms of cancer and other life-threatening diseases.

Psychedelics and trauma

    • People who develop PTSD from military service or physical or sexual violence commonly experience depression and anxiety.
    • Based on this research, my team and I hypothesize that psychedelic sessions might have an advantage over traditional prescription antidepressants for patients with cancer-related depression or anxiety because it may help them deal with their underlying trauma.
    • Patients stated that the psychedelic sessions helped them process the intense feelings they were repressing without being overwhelmed.

Unknowns in psychedelic therapy

    • A number of the advanced cancer studies we examined included people with a history of psychedelic use.
    • People with prior positive recreational psychedelic experiences may be more likely to participate in these studies than those who experienced a “bad trip” or were opposed to recreational drugs altogether.
    • Additionally, even though the placebo was made to look identical, it is unlikely that patients or caregivers were fooled if it did not elicit a psychedelic effect.

Next steps for psychedelics

    • More research is needed on effectiveness of psychedelics to treat anxiety and depression in cancer patients.
    • Exploring psychedelic treatments for patients with other life-threatening diseases that cause trauma, anxiety or depression could clarify their potential therapeutic benefits.
    • Were the Food and Drug Administration to approve psychedelics for this kind of use, the agency would need to figure out how these psychedelics can be used legally.

China Escitalopram Market Research Report 2021: Sales 2016-2020, Major Manufacturers, Prices 2020-2021, Prospects 2021-2025 - ResearchAndMarkets.com

Retrieved on: 
Giovedì, Marzo 10, 2022
Health, Pharmaceutical, Research report, China Energy Research Report, Life, Escitalopram, The Different Company, Urbanization, Dosage form, Depression, Patient, COVID-19, Steven N. S. Cheung, CAGR, Animal, Pharmaceutical industry, Motor vehicle, Generic drug

The "Research Report on China's Escitalopram Market, 2021-2025" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Research Report on China's Escitalopram Market, 2021-2025" report has been added to ResearchAndMarkets.com's offering.
  • Companies with a relatively large market share of escitalopram in China include Sichuan Kelun Pharmaceutical, Jewim Pharmaceutical, Hunan Dongting Pharmaceutical and Jinhua CONBA.
  • From 2021 to 2025, it is likely to see a recovery increase in the market size of escitalopram in China.
  • Prospects of China's Escitalopram Market, 2021-2025
    2 Sales of Escitalopram in China, 2016-2020
    2.3 Sales of Escitalopram in China by Dosage Form, 2016-2020
    3 Analysis of Major Escitalopram Manufacturers in China, 2020
    3.3 Sichuan Kelun Pharmaceutical Co., Ltd.
    3.4 Jewim Pharmaceutical (Shandong) Co., Ltd.
    3.5 Hunan Dongting Pharmaceutical Co., Ltd.
    3.6 Zhejiang Jinhua CONBA Bio-pharm.

Millions to gain access to Psychedelic Psychotherapy in bid to fight pandemic induced depression and anxiety

Retrieved on: 
Giovedì, Giugno 17, 2021
Psychoactive drugs, Selective serotonin reuptake inhibitors, Drugs, Antidepressants, Chemical compounds, Serotonin reuptake inhibitor, Fluoxetine, Citalopram, Escitalopram, Development and discovery of SSRI drugs, Management of depression

Launched today for the first time Journey Clinical provides self-employed psychotherapists and independent practices the necessary access to a prescriber to offer ketamine-assisted psychotherapy (KAP) to patients.

Key Points: 
  • Launched today for the first time Journey Clinical provides self-employed psychotherapists and independent practices the necessary access to a prescriber to offer ketamine-assisted psychotherapy (KAP) to patients.
  • One-in-ten Americans are taking anti-depressant medication with the majority taking selective serotonin reuptake inhibitors (SSRIs) such as Prozac, Celexa and Lexapro.
  • However an increasing number of people believe anxiety and depression stems from internalised trauma which SSRIs fail to tackle.
  • The pandemic has exacerbated the mental health crisis, with some 100 million now estimated to be dealing with depression today.

Global Antidepressants Market Report 2021: COVID-19 Causes a Surge in Demand for Antidepressant Drugs as Mental Health Problems Rise - ResearchAndMarkets.com

Retrieved on: 
Lunedì, Aprile 26, 2021
Pharmaceutical, Health, Mental health, Selective serotonin reuptake inhibitors, Antidepressants, Chemical compounds, Psychoactive drugs, Organic compounds, Major depressive disorder, Escitalopram, Citalopram, Management of depression

Therefore, rising cases of mental health disorders is expected to drive the growth of the antidepressant market.\nThe side-effects of antidepressant drugs is a key factor hampering the growth of the antidepressant market.

Key Points: 
  • Therefore, rising cases of mental health disorders is expected to drive the growth of the antidepressant market.\nThe side-effects of antidepressant drugs is a key factor hampering the growth of the antidepressant market.
  • For instance, the antidepressants Lexapro (escitalopram) and Celexa (citalopram), both are used to treat depression and Lexapro also helps for treating anxiety.
  • People who are already living with mental health problems are experiencing increased stress levels over the COVID-19 outbreak.
  • This has triggered the demand for antidepressant drugs.\nThe treatment for resistant depression is a key trend in the antidepressant market.

GeneSight Psychotropic Test’s Combinatorial Approach Proves Better than Single-Gene Testing at Predicting Patient Outcomes and Medication Blood Levels

Retrieved on: 
Lunedì, Febbraio 8, 2021
Chemical compounds, RTT, Selective serotonin reuptake inhibitors, Chemistry, Organic compounds, Genomics, Pharmacogenomics, Pharmacology, Pharmacy, Escitalopram, Citalopram

SALT LAKE CITY, Feb. 08, 2021 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in genetic testing and precision medicine, announced today the peer-reviewed journal Psychiatry Research has published a new analysis showing the combinatorial approach available in the GeneSight Psychotropic test is better than single-gene testing at predicting patient outcomes and medication blood levels.

Key Points: 
  • SALT LAKE CITY, Feb. 08, 2021 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in genetic testing and precision medicine, announced today the peer-reviewed journal Psychiatry Research has published a new analysis showing the combinatorial approach available in the GeneSight Psychotropic test is better than single-gene testing at predicting patient outcomes and medication blood levels.
  • Using data from the Genomics Used to Improve DEpression Decisions (GUIDED) randomized-controlled trial, the study evaluated the ability of the combinatorial approach available in the GeneSight Psychotropic test to predict patient outcomes and medication blood levels compared to Clinical Pharmacogenetics Implementation Consortium(CPIC) single-gene recommendations.
  • Medication Blood Levels The analysis of the combinatorial pharmacogenomic test and single-gene guidelines showed the predictive ability of the GeneSight combinatorial approach was better.
  • This is the second study evaluating the combinatorial approach of the GeneSight test to be published inPsychiatry Research.The earlier study, published in May 2020, demonstrated the combinatorial approach available in the GeneSight Psychotropic test was better at predicting citalopram and escitalopram blood concentrations when compared to single-gene testing.

New Study Demonstrates GeneSight Psychotropic Better Predicts Blood Drug Levels When Compared to Single-Gene Testing

Retrieved on: 
Lunedì, Giugno 8, 2020
Selective serotonin reuptake inhibitors, Branches of biology, Chemical compounds, RTT, Chemistry, Escitalopram, Nitriles, Citalopram, Medical genetics, Pharmacogenomics, Genetic testing

The study demonstrated the GeneSight Psychotropic test is better at predicting citalopram and escitalopram blood concentrations when compared to single-gene testing.

Key Points: 
  • The study demonstrated the GeneSight Psychotropic test is better at predicting citalopram and escitalopram blood concentrations when compared to single-gene testing.
  • The GeneSight test assesses and weighs multiple gene factors, which more accurately predicts blood drug levels and identifies more patients with significant gene-drug interactions who would be missed by single-gene testing, said Michael R. Jablonski, Ph.D., vice president of medical affairs, Myriad Neuroscience.
  • The study provides further evidence to support the superiority of GeneSights combinatorial testing relative to single-gene methodologies and guideline recommendations.
  • Furthermore, combinatorial pharmacogenomic testing explained more variance in citalopram blood levels when compared to single-gene testing.

LEXAPRO Drug Profile, 2019 - Patents, Clinical Trials, Drug Prices, Annual Sales Revenues and Raw API Sources - ResearchAndMarkets.com

Retrieved on: 
Lunedì, Gennaio 14, 2019
Health, Pharmaceutical, Chemistry, RTT, Enantiopure drugs, Selective serotonin reuptake inhibitors, Escitalopram, Nitriles, Pharmaceutical industry, Medication

The "LEXAPRO Drug Profile, 2019" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "LEXAPRO Drug Profile, 2019" report has been added to ResearchAndMarkets.com's offering.
  • LEXAPRO Drug Profile, 2019 is part of a deep library of business intelligence on biopharmaceutical drugs.
  • The report focuses on LEXAPRO and covers the following critical aspects of this drug:

New Data Added to TRINTELLIX® (vortioxetine) Labeling Demonstrated Superiority Over Escitalopram in Improving SSRI-Induced Sexual Dysfunction in Patients with Major Depressive Disorder

Retrieved on: 
Lunedì, Ottobre 22, 2018
Chemistry, Selective serotonin reuptake inhibitors, Organic chemistry, Cell signaling, Antidepressants, RTT, Amines, Nitriles, Vortioxetine, Escitalopram, Sertraline, Citalopram

The TRINTELLIX U.S. prescribing information now includes head-to-head clinical study data that demonstrated superiority to a commonly-used selective serotonin reuptake inhibitor (SSRI), Lexapro (escitalopram) in improving treatment-emergent sexual dysfunction (TESD).

Key Points: 
  • The TRINTELLIX U.S. prescribing information now includes head-to-head clinical study data that demonstrated superiority to a commonly-used selective serotonin reuptake inhibitor (SSRI), Lexapro (escitalopram) in improving treatment-emergent sexual dysfunction (TESD).
  • These data build upon the voluntary and prospective reports of sexual dysfunction with TRINTELLIX in clinical trials.
  • In the five years since FDA approval on September 30, 2013, more than 845,000 patients have been prescribed TRINTELLIX.
  • This is the second time this year FDA has approved an sNDA for TRINTELLIX to add new data to the TRINTELLIX U.S. labeling.